• Publications
  • Influence
Estimating the mean and variance from the median, range, and the size of a sample
BackgroundUsually the researchers performing meta-analysis of continuous outcomes from clinical trials need their mean value and the variance (or standard deviation) in order to pool data. However,Expand
  • 3,988
  • 102
  • PDF
Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*
DESCRIPTION Although approximately 85 million units of red blood cells (RBCs) are transfused annually worldwide, transfusion practices vary widely. The AABB (formerly, the American Association ofExpand
  • 871
  • 26
  • PDF
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Abstract Objective To investigate whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials fundedExpand
  • 1,785
  • 21
  • PDF
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
CONTEXT The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stemExpand
  • 641
  • 21
  • PDF
Erythropoietin or darbepoetin for patients with cancer.
BACKGROUND Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant human erythropoietinExpand
  • 236
  • 20
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
Anemia resulting from cancer or its treatment is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin. To address uncertainties regardingExpand
  • 494
  • 18
  • PDF
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
CONTEXT The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin are licensed to treat chemotherapy-associated anemia in patients with nonmyeloid malignancies. Although systematicExpand
  • 683
  • 17
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Summary. The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinicalExpand
  • 1,825
  • 16
  • PDF
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
This is an updated systematic review of 57 trials and 9353 cancer patients from articles, abstracts, and reports published between January 1, 1985, and April 30, 2005, on the effects of epoetin alfaExpand
  • 551
  • 12
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials
Objective To examine the evidence on the benefits and harms of screening for prostate cancer. Design Systematic review and meta-analysis of randomised controlled trials. Data sources ElectronicExpand
  • 315
  • 12
  • PDF